Pfizer facing three Celebrex antitrust cases

10-07-2014

Pfizer is facing three class actions that allege the pharmaceutical company improperly obtained a patent covering its arthritis drug Celebrex (celecoxib) and used it to force generic drug makers into settlements that delay their entry into the market, Law360 has reported.


Pfizer, Celebrex, antitrust

LSIPR